Vencanna Ventures Inc. is a venture capital firm focused on investing in early-stage cannabis-related businesses. The company faces significant financial challenges, evidenced by a low gross margin of 9.6% and a concerning EBITDA margin of -75.5%, indicating operational inefficiencies. Additionally, its negative net margin of -96.2% raises red flags about profitability. However, the debt-to-equity ratio of 0.56 suggests manageable leverage. Overall, the company's financial health score of 29/100 highlights substantial risks that potential investors should consider.
Loading financial metrics...
Company is burning $232K per quarter with $598K in cash. Approximately 2.6 quarters of runway at current burn rate.
Company posted a loss of $-3.9M over the last year, representing 96.2% of revenue.
Debt of $2.1M is 3.5x the company's cash position of $598K.
Operating cash flow has been negative for 3 consecutive quarters, burning $927K over the last year.
Exceptional revenue growth of 1963.9% YoY demonstrates strong market demand and competitive positioning.
Gross margin expanded by 397.0 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 92.4pp, demonstrating strong operational leverage.
Both gross margin (+397.0pp) and operating margin (+92.4pp) are expanding simultaneously, indicating the company is scaling profitably.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-FY (April 30, 2025)